Understanding the Connection between Idiopathic Pulmonary Fibrosis and PH

Recorded on Thursday, Sept. 14.

Idiopathic pulmonary fibrosis is the most common type of interstitial lung disease. ILD is characterized by scarring and/or inflammation of support tissue in the lungs. People with idiopathic PF can develop pulmonary hypertension due to a stiff left side of the heart, obstructive sleep apnea or blood clots.

Navneet Singh, MD, MBA, and Christopher King, MD, will discussedthe tests needed for an accurate IPF and PH diagnosis and the latest treatment options available for each disease.

About the Speakers

Christopher King, MD

Christopher King, MD, is a pulmonologist with the Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital in Falls Church, Virginia.  He earned his Bachelor of Science in biology with a concentration in cell and molecular biology at Loyola College in Baltimore. Dr. King received his medical degree from the University of Maryland and completed both his internal medicine residency and fellowship at Walter Reed Army Medical Center in Bethesda, Maryland. While on active duty, Dr. King served in multiple locations including El Paso, Texas, Korea and Afghanistan.   

In addition to serving as the associated medical director of the Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital, Dr. King is the director of the Pulmonary Fibrosis Foundation Center; the associate medical director of the Pulmonary Hypertension and CTEPH Program; and the systems medical director of inpatient respiratory therapy for Inova Fairfax Hospital. Dr. King’s primary interest is the critical care of advanced lung disease.  He has numerous peer-reviewed publications on venous thromboembolism, ILD, PH and lung transplant.

Navneet Singh, MD, MBA

Navneet Singh, MD, MBA, is an attending physician and post-doctoral research fellow in the Division of Pulmonary, Critical Care & Sleep Medicine and the Pulmonary Hypertension Center at Brown University in Providence, Rhode Island. Dr. Singh has a clinical and research interest in pulmonary vascular disease and has spent his medical career caring for disadvantaged patients. He is committed to improving the lives of people who struggle with access to care and for those with diseases that disrupt quality of life as severely as pulmonary hypertension.